Sonnet BioTherapeutics Announces FDA Acceptance Of The Company's IND For SB221 Clinical Trial Of SON-1010 Combined With Atezolizumab In The US
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics has announced that the FDA has accepted the company's IND for the SB221 clinical trial of SON-1010 combined with Atezolizumab in the US.
August 16, 2023 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonnet BioTherapeutics' IND for the SB221 clinical trial of SON-1010 combined with Atezolizumab has been accepted by the FDA, potentially leading to positive impacts on the company's stock.
The FDA's acceptance of Sonnet BioTherapeutics' IND for the SB221 clinical trial is a significant regulatory milestone for the company. This could potentially lead to positive investor sentiment and an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100